ArticleJournal of hepatology2021
Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.
Abstract readLetterComment
In one paragraph
Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Effects of Weight Loss on Adipose and Muscular Neuropilin 1 mRNA Expression in Obesity: Potential Implication in SARS-CoV-2 Infections?Obesity facts · 2022Trial
- Angiotensin-Converting Enzyme Inhibitors to Prevent Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Scientific Speculation or an Opportunity to Improve Real Clinical Practice?International journal of molecular sciences · 2025Review
- Post-COVID-19 Pandemic Sequelae in Liver Diseases.Life (Basel, Switzerland) · 2025Review
- Characteristics and mechanisms of liver injury caused by emerging infectious diseases.Frontiers in immunology · 2025Review
- Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.World journal of gastroenterology · 2024Article
- Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications.World journal of gastroenterology · 2024Review
- Molecular mechanisms underlying SARS-CoV-2 hepatotropism and liver damage.World journal of hepatology · 2024Article
- SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH.JHEP reports : innovation in hepatology · 2024Article
- Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury.Viruses · 2023Review
- The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.Viruses · 2023Review
- Coronavirus Disease-2019 and Implications on the Liver.Clinics in liver disease · 2023Review
- COVID-19 and the liver: Are footprints still there?World journal of gastroenterology · 2023Review
- The causal association between polycystic ovary syndrome and susceptibility and severity of COVID-19: a bidirectional Mendelian randomization study using genetic data.Frontiers in endocrinology · 2023Article
- COVID-19 and MAFLD/NAFLD: An updated review.Frontiers in medicine · 2023Review
- Maternal fructose boosts the effects of a Western-type diet increasing SARS-COV-2 cell entry factors in male offspring.Journal of functional foods · 2023Article
- Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.Medicina (Kaunas, Lithuania) · 2022Review
- The Role of Non-Alcoholic Fatty Liver Disease in Infections.Life (Basel, Switzerland) · 2022Review
- Machine learning insights concerning inflammatory and liver-related risk comorbidities in non-communicable and viral diseases.World journal of gastroenterology · 2022Review
- COVID-19-induced liver injury in adult patients: A brief overview.World journal of virology · 2022Review
- Article
Corrections and comments
- AssociatedDataset
- Comment on
Authors and funding
14 authors.
Marcos F FondevilaDepartment of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain.
Maria Mercado-GómezLiver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, and CIBER de Enfermedades Hepaticas y Digestivas (CIBERehd), Spain.
Amaia RodríguezCIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain; Obesity Area, Clínica Universidad de Navarra and IdiSNA, Pamplona, Spain.
Maria J Gonzalez-RellanDepartment of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain.
Paula IruzubietaDepartment of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain.
Víctor ValentíCIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain; Obesity Area, Clínica Universidad de Navarra and IdiSNA, Pamplona, Spain.
Javier EscaladaCIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain; Obesity Area, Clínica Universidad de Navarra and IdiSNA, Pamplona, Spain.
Markus SchwaningerInstitute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.
Vincent PrevotUniv. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, European Genomic Institute for Diabetes (EGID), F-59000 Lille, France.
Carlos DieguezDepartment of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain.
Javier CrespoDepartment of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Research Institute Marqués de Valdecilla (IDIVAL), Santander, Spain.
Gema FrühbeckCIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain; Obesity Area, Clínica Universidad de Navarra and IdiSNA, Pamplona, Spain.
Maria L Martinez-ChantarLiver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, and CIBER de Enfermedades Hepaticas y Digestivas (CIBERehd), Spain. Electronic address: mlmartinez@cicbiogune.es.
Ruben NogueirasDepartment of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain; Galician Agency of Innovation (GAIN), Santiago de Compostela, Spain. Electronic address: ruben.nogueiras@usc.es.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Non-alcoholic Fatty Liver DiseaseHumansObesityRetrospective StudiesSARS-CoV-2Virus Internalization
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.